Reevaluating Asthma Severity Assessment: The Role of Steroid Use and Short-Acting Inhaler Refills
Asthma severity and control are traditionally assessed based on medication use and exacerbation frequency. However, emerging evidence suggests that relying solely on these parameters—particularly current medication use and recent exacerbations—fails to accurately predict future exacerbations. A more comprehensive assessment, incorporating the number of systemic corticosteroid courses for past exacerbations and the frequency of short-acting bronchodilator (SAB) refills, provides a more reliable measure of asthma control and risk stratification.
Current guidelines often categorize asthma severity based on controller medication usage and recent exacerbation history. However, this method has significant limitations:
Medication Use Does Not Reflect Control: Patients with poorly controlled asthma may be under-prescribed controller therapy, leading to an underestimation of severity.
Single Exacerbations Are Poor Predictors: A single recent exacerbation does not necessarily indicate a pattern of instability, nor does its absence ensure stability.
Patient Adherence Varies: Inconsistent medication adherence can confound assessments based on prescription refills or reported use.
The frequency of systemic corticosteroid use for asthma exacerbations is a strong indicator of disease control. Frequent steroid bursts (≥2 per year) suggest a persistent risk of future exacerbations and indicate the need for therapy escalation. Studies show that patients requiring multiple steroid courses exhibit higher morbidity, airway remodeling, and an increased risk of emergency department visits or hospitalizations.
SAB usage reflects the degree of symptom burden and reliever dependence. Frequent refills (e.g., >3 canisters per year) correlate with increased exacerbation risk and indicate suboptimal control, even in patients who do not report daily symptoms. Overreliance on SABs suggests inadequate controller therapy, making it a valuable metric for risk assessment.
A dual approach that considers both systemic corticosteroid use and SAB refill frequency offers a more predictive model for asthma control assessment:
Low Risk: <2 systemic corticosteroid courses per year and ≤3 SAB canister refills per year
Moderate Risk: 2–3 systemic corticosteroid courses per year and 4–6 SAB canister refills per year
High Risk: >3 systemic corticosteroid courses per year and >6 SAB canister refills per year
Patients in the moderate and high-risk categories require proactive management, including step-up controller therapy, adherence optimization, and possibly biologic therapy for severe asthma.
Assessing asthma severity solely based on current medication use and recent exacerbations does not provide a reliable prediction of future exacerbations. Incorporating systemic corticosteroid course frequency and SAB refill data enhances risk stratification and guides appropriate management adjustments. Future guidelines should integrate these metrics to optimize asthma care and reduce morbidity.
If you need to book an appointment for your allergies or asthma, you can book your appointment online, or call (212) 247-7447.